are currently so preoccupied with the funding impli- cations of change. But rejoicing may yet be premature, for the spectre of a higher prevalence of factor VIII inhibitors in patients receiving high potency concen- trates needs to be looked at and, we hope, dispelled. I Cash JD. Coagulation factor VIII concentrates and the marketplace.
No takes yet. Share an insight, caveat, or question.
A 1991 study studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: